In the latest trading session, Hologic (HOLX) closed at $80.46, marking a -0.46% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.27%. Meanwhile, the Dow experienced a rise of 0.65%, and the technology-dominated Nasdaq saw an increase of 0.26%. Shares of the medical device maker have appreciated by 0.01% over the course of the past month, outperforming the Medical sector's loss of 4.14% and lagging the S&P 500's gain of 2%. The investment community will be paying ...

Hologic, Inc.'s (HOLX) Diagnostics segment, excluding COVID-19 assay and related revenues, is expected to have significantly benefited from the robust Panther utilization in its Molecular Diagnostics franchise. Higher gantry deliveries and robust service revenues are likely to have contributed to the Breast Health segment's performance. Furthermore, MyoSure is likely to have emerged as the key driver of the GYN Surgical division's revenues. We anticipate that the company's fiscal 2024 fourth-quarter financi ...

Hologic (HOLX) closed at $81.15 in the latest trading session, marking a -0.51% move from the prior day. This move lagged the S&P 500's daily loss of 0.18%. Elsewhere, the Dow saw a downswing of 0.8%, while the techheavy Nasdaq appreciated by 0.27%. Coming into today, shares of the medical device maker had gained 0.22% in the past month. In that same time, the Medical sector lost 3.03%, while the S&P 500 gained 4.46%. The upcoming earnings release of Hologic will be of great interest to investors. The compa ...

Hologic (HOLX) is set to release fourth-quarter fiscal 2024 results on Nov. 4 after the closing bell.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.The Zacks Consensus Estimate for fourth-quarter earnings suggests a 14.6% increase year over year to $1.02 per share. The estimate has remained stable in the past 60 days. The Zacks Consensus Estimate for fourth-quarter revenues currently stands at $979.3 million, a 3.6% improvement compared to the last year.Image Source: Zacks Investme ...

On Monday, Hologic Inc HOLX agreed to acquire Gynesonics, Inc. for approximately $350 million. Gynesonics is a privately held medical device company that develops minimally invasive solutions for women's health. California-based Gynesonics develops and sells the Sonata System, a technology intended for diagnostic intrauterine imaging and transcervical treatment of certain symptomatic uterine fibroids, including those associated with heavy menstrual bleeding. The Sonata System combines real-time intrauterine ...

Hologic, Inc. (HOLX) entered the Breast Cancer Awareness Month by ringing the Nasdaq opening bell for the 18th year. As part of this annual tradition, Hologic launched a comprehensive patient education campaign named BustTheMyth. The campaign is aimed at dispelling myths about breast cancer, mammograms and breast density. The latest announcement highlights Hologic's commitment to advancing technology and improving patient outcomes across the continuum of breast health. Significance of Hologic's BustTheMyth ...

October is celebrated as breast cancer awareness month annually, and Hologic (HOLX) , this time too, honored the occasion by ringing the Nasdaq opening bell for the 18 consecutive time. While celebrating this yearly tradition, the company came into the limelight as it also introduced a comprehensive education campaign aimed at debunking common myths about breast cancer, mammograms and breast density. Aptly named #BustTheMyth, the program stresses the need for practical education alongside cutting-edge techn ...

The most recent trading session ended with Hologic (HOLX) standing at $80.26, reflecting a +0.48% shift from the previouse trading day's closing. This move lagged the S&P 500's daily gain of 0.97%. At the same time, the Dow added 0.3%, and the tech-heavy Nasdaq gained 1.45%. The medical device maker's stock has dropped by 3.4% in the past month, exceeding the Medical sector's loss of 3.72% and lagging the S&P 500's gain of 5.41%. Market participants will be closely following the financial results of Hologic ...

Hologic (HOLX) has been gaining from new strategic product launches across Diagnostics and Breast Health. However, macroeconomic issues and unfavorable FX headwinds continue to impede growth. The stock carries a Zacks Rank #3 (Hold) currently. Major Factors Driving HOLX Stock Growth Among Hologic's advanced diagnostic products, primary revenue-generating ones are molecular diagnostic assays, which run on advanced instrumentation systems (Panther, Panther Fusion and Tigris), ThinPrep cytology system and the ...

Hologic, Inc.'s (HOLX) sustained momentum in the Molecular Diagnostics portfolio is poised to fuel its growth in the upcoming quarters. A crucial part of its long-term strategy, the company is planning to expand into more countries overseas, which are largely untapped. It is also using its strong cash position strategically by focusing on acquisitions and share buybacks. Meanwhile, concerns remain over the impact of macroeconomic challenges on Hologic's operations. Adverse currency impact also adds to the w ...